Titan Pharmaceuticals, Inc.

Navigate Titan Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Who We Are
    • IP Portfolio
    • Management Team
    • Board of Directors
    • Careers
  • Technology
  • Pipeline
    • Kappa Opioid Receptor Agonist
    • Nalmefene Implant
  • News
    • Overview
    • Press Releases
    • Events
    • Presentations
    • In the News
    • Publications
    • Posters
    • Media Resources
  • Investors
    • Investor Relations
    • Overview
    • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
    • Company Info
    • Company Information
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
    • Titan FCOI Policy
    • Stock Data
    • Quote
    • Charts
    • Historical Data
    • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact
  • Search

Press Releases

  • Home
  • News
  • Press Releases
News

Navigate News

  • Overview
  • Press Releases
  • Events
  • Presentations
  • In the News
  • Publications
  • Posters
  • Media Resources

Press Releases

  • All News
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009

Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence

May 26, 2016

Titan Pharmaceuticals Reports First Quarter 2016 Financial Results

May 10, 2016

Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results

May 4, 2016

Titan Pharmaceuticals Announces Presentation of Probuphine Phase 3 Data at American Society of Addiction Medicine Annual Conference

April 15, 2016

Titan Pharmaceuticals Reports Full Year and Fourth Quarter 2015 Financial Results

March 15, 2016

Titan Pharmaceuticals to Present at 28th Annual ROTH Conference

March 8, 2016

Titan Pharmaceuticals Schedules Conference Call to Review Fourth Quarter and Full Year 2015 Financial Results

March 8, 2016

Titan Pharmaceuticals Receives Feedback From FDA on Ropinirole Implant Development Program for Parkinson's Disease

March 7, 2016

Titan Pharmaceuticals Announces Notification of FDA Action Date Extension for Probuphine

February 19, 2016

Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction

January 12, 2016

  • « Previous
  • 1
  • 2
  • 3
  • Next »
© 2022 Titan Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Titan FCOI Policy Disclaimer Sitemap